Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $22,950.64 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 9,406 shares of the business’s stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $2.44, for a total value of $22,950.64. Following the completion of the transaction, the chief executive officer now owns 867,251 shares in the company, valued at approximately $2,116,092.44. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Sera Prognostics Stock Up 4.7%

Shares of NASDAQ SERA opened at $2.22 on Monday. Sera Prognostics, Inc. has a fifty-two week low of $2.10 and a fifty-two week high of $9.91. The business has a 50 day moving average price of $3.48 and a two-hundred day moving average price of $5.49. The firm has a market cap of $83.61 million, a PE ratio of -2.24 and a beta of 0.99.

Sera Prognostics (NASDAQ:SERA) last released its earnings results on Wednesday, May 14th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets acquired a new stake in shares of Sera Prognostics in the 4th quarter valued at about $28,000. XTX Topco Ltd acquired a new stake in Sera Prognostics during the first quarter valued at approximately $39,000. Price T Rowe Associates Inc. MD bought a new position in Sera Prognostics during the 4th quarter worth approximately $93,000. Gotham Asset Management LLC bought a new position in Sera Prognostics during the 4th quarter worth approximately $96,000. Finally, Walleye Capital LLC acquired a new position in shares of Sera Prognostics in the 4th quarter worth approximately $98,000. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.